Radiation + TKI Therapy for Lung Cancer

Phase 2

Recruiting

Led By Jonathan Thompson, MD, MS

Research Sponsored by Medical College of Wisconsin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up start of tki treatment to 18 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if giving radiation to the main lung tumor before starting a specific drug can help patients with advanced lung cancer live longer without their disease getting worse.

Who is the study for?

This trial is for people with advanced non-small cell lung cancer that hasn't been treated yet. It's specifically for those whose cancer has certain genetic changes (driver mutations) and who are healthy enough to undergo radiation therapy followed by a targeted drug treatment.

What is being tested?

The study is testing if giving radiation to the main lung tumor before starting TKI medication can help delay the cancer from getting worse. All participants will receive this sequence of treatments, and their progress will be closely monitored.

What are the potential side effects?

Radiation may cause skin irritation, fatigue, shortness of breath, or coughing. TKI therapy could lead to diarrhea, rash, liver issues, or other side effects depending on the specific drug used.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ start of tki treatment to 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~start of tki treatment to 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and start of tki treatment to 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Progression Free Survival

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Radiation therapy followed by mutation-matched TKI treatmentExperimental Treatment2 Interventions

Part 1 will enroll subjects who will be given radiation doses at the discretion of the treating physicians. Subjects with actionable driver mutation will continue to Part 2 and receive a standard-of-care TKI at the discretion of the treating oncologist.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Radiation Therapy

2017

Completed Phase 3

~7250

Do I qualify?Apply below to find out